ArriVent BioPharma, Inc. AVBP 深 滬
已收盤 04-02 16:00:00 美东时间
24.89
+0.670
+2.77%
華盛通- 最 高25.25
- 今 開23.63
- 成交量 36.29万股
- 最 低 23.485
- 昨 收 24.22
- 總市值 11.00亿
- 52周最高 27.22
- 市盈率 靜 --
- 換手率 0.82%
- 52周最低 16.10
- 委 比 -73.39%
- 總股本 4420.16万
- 歷史最高 36.37
- 量 比 0.72
- 振 幅 7.29%
- 歷史最低 14.35
- 每 手 1
- 風險率 2.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 瑞穗上调MongoDB至"跑赢大市"，目标价从290美元升至325美元；麦格理下调小鹏评级至"中性" 目标价从24美元降至19美元
今日重点评级关注：HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从12美元升至13美元；Litchfield Hills：维持Star Equity Holdings"买入"评级，目标价从21美元升至28美元
03-24 10:07
ArriVent BioPharma To Reveal Two Preclinical Posters On The EGFR Inhibitor Firmonertinib And On the Novel Dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 At The 2026 AACR Annual Meeting
Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal modelsSuperior anti-tumor activity of ARR-002 in
03-18 05:19
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
美股大行评级 | 潜在涨幅183%！迈威尔科技获10家机构上调目标价最高至164美元；伯灵顿百货、好市多、Ciena、Samsara等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持BridgeBio Oncology"买入"评级，目标价从27美元升至29美元；韦德布什：维持WAVE Life Sciences"跑赢大市"评级，目标价从33美元升至35美元
03-09 11:47
HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $44
HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $42 to $44.
03-06 20:19
ArriVent Doses First Patient In Phase 3 ALPACCA Trial Of Firmonertinib For The Treatment Of EGFR-Mutant NSCLC
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support potential
2025-12-22 21:11
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors ...
2025-12-17 02:17
美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
2025-12-11 10:33
BTIG Initiates Coverage On ArriVent BioPharma with Buy Rating, Announces Price Target of $45
BTIG analyst Justin Zelin initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces Price Target of $45.
2025-12-10 20:34
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
2025-11-26 10:07
